New treatment for neuromyelitis optica flare-ups
Part of Brain & nervous system, Eyes & vision, Immune system & allergy clinical trials.
This trial tests a new medicine (NouvSoma001) for people with neuromyelitis optica (NMOSD) who are having a flare-up. The goal is to see if the treatment is safe and if it helps reduce symptoms like pain and trouble moving.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with NMOSD and tested positive for AQP4 antibodies.
- Your most recent symptoms must have started within the last 7 days, and you should be having severe pain, trouble with leg movement, or bladder/bowel problems.
- You need to be between 18 and 65 years old.
- Before this episode, your disability from NMOSD should be mild (an EDSS score of 4 or less).
- If you could become pregnant, you must have a negative pregnancy test and agree to use effective birth control during the trial.
- You must be able to give informed consent (or have a legal representative do so), and you cannot have certain health issues like low blood counts, liver or kidney problems, or a history of heart attack or stroke in the last 12 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a blood filtering procedure called Protein A immunoadsorption for people having an acute episode of neuromyelitis optica spectrum disorder (NMOSD). It may help remove harmful antibodies from your blood and reduce symptoms.
This trial tests a new medication called JYP0061 for people with NMOSD who are currently experiencing a sudden worsening of symptoms (acute attack). It aims to see if the drug can help control the attack and improve outcomes.
This trial tests an investigational drug called B001 for people with NMOSD who have had recent relapses. The goal is to see if it can reduce future flare-ups.
This early-phase trial tests CT103A “CAR-T” cell therapy to treat certain relapsing or treatment-resistant autoimmune diseases that affect the nervous system. It aims to see whether the cells are safe and may help reduce disease activity when standard treatments haven’t controlled symptoms.
This trial tests a new stem cell treatment for people with a severe relapse of neuromyelitis optica (NMO), a rare autoimmune disease that affects the eyes and spinal cord. The treatment may help reduce damage and improve recovery.
This study tests a new treatment called CC-97540 (a type of CAR T-cell therapy) for people with neuromyelitis optica spectrum disorder (NMOSD), which is an autoimmune disease that affects the eyes and spinal cord. The goal is to see if this treatment is safe and tolerable.
Hear when a new Neuromyelitis Optica Spectrum Disorders trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.